Search

Your search keyword '"Park, Hyoung Keun"' showing total 298 results
Start Over Author "Park, Hyoung Keun"
298 results on '"Park, Hyoung Keun"'

5. What is the Cause of Recurrent Urinary Tract Infection? Contemporary Microscopic Concepts of Pathophysiology

Author

Kim, Aram, Ahn, Jaehak, Choi, Woo Suk, Park, Hyoung Keun, Kim, Sehwan, Paick, Sung Hyun, and Kim, Hyeong Gon

Subjects
Urinary tract infection, business.industry, Urology, Urinary system, Review Article, Disease, urologic and male genital diseases, medicine.disease_cause, Diseases of the genitourinary system. Urology, female genital diseases and pregnancy complications, Review article, Neurology, Recurrence, Infectious disease (medical specialty), Cystitis, Immunology, Escherichia coli, Extracellular, Medicine, RC870-923, Neurology (clinical), Microbiome, Urothelium, business
Abstract

Urinary tract infections (UTIs) are the most common infectious disease and are mainly caused by Escherichia coli. In this review, we introduce the current concept of recurrent UTI (rUTI) based on recent research dealing with pathophysiology of the disease. Although urine is considered sterile, recent studies dealing with microbiome have proposed different ideas. UTIs have typically been considered as extracellular infections, but recently, uropathogenic Escherichia coli (UPEC) has been shown to bind and replicate in the urothelium to make intracellular bacterial communities. Binding UPECs might proceed in many ways including extracellular expulsion for clearance or survival and quiescent intracellular reservoirs that can cause rUTI. Moreover, it is also suggested that other important factors, such as lipopolysaccharide and multimicrobial infection, can be the cause of rUTI. This review article reveals a key mechanism of recurrence and discusses what makes a pathway of resolution or recurrence in a host after initial infection.

Published
2021

10. An Efficient Iteration Decoding Stopping Criterion for Turbo Codes

Author

Shim, Byoung-Sup, Park, Hyoung-Keun, Kim, Sun-Youb, Ra, Yu-Chan, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Doug, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Gervasi, Osvaldo, editor, and Gavrilova, Marina L., editor

Published
2007
Full Text
View/download PDF

49. Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review.

Author

Kim, Aram, Kim, Min Seo, Ahn, Jae-Hak, Choi, Woo Suk, Park, Hyoung Keun, Kim, Hyeong Gon, and Paick, Sung Hyun

Subjects
BLADDER cancer, ANDROGEN deprivation therapy, CANCER treatment, REDUCTASE inhibitors, CANCER relapse, BLADDER tumors, RESEARCH, ANTIANDROGENS, META-analysis, ANDROGENS, RESEARCH methodology, SYSTEMATIC reviews, DISEASE incidence, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, PROSTATE tumors, ENZYME inhibitors
Abstract

Purpose: This study aimed to investigate the effect of androgen suppression therapy (AST), comprising a 5-α reductase inhibitor (5-ARi) and androgen deprivation therapy (ADT), on the risk of bladder cancer incidence, recurrence, and mortality.Materials and Methods: We used the PRISMA statement to report the methods and results of this meta-analysis. Bladder cancer incidence, recurrence, and mortality after 5-ARi treatment and ADT were assessed using risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs). The protocol of this study is registered in the PROSPERO database (No. CRD42018118627).Results: We analyzed nine studies (n = 377,427) assessing the secondary effect of AST, with a mean follow-up period of 6 years (range, 2-13 years). Our result showed that the incidence of bladder cancer was significantly reduced when 5-ARi treatment (RR, 0.69; 95% CI, 0.58-0.81; I2 =0%) and ADT (HR, 0.81; 95% CI, 0.70-0.94; I2 =33%) were initiated before diagnosing bladder cancer. When treatment was initiated after diagnosing bladder cancer, 5-ARi treatment reduced cancer-specific mortality (RR, 0.29; 95% CI, 0.20-0.42; I2 =4.1%), whereas ADT reduced bladder cancer recurrence (HR, 0.30; 95% CI, 0.19-0.49; I2 =0%).Conclusions: This study corroborates that the use of 5-ARi and ADT could be helpful in managing bladder cancer and should not be limited to prostatic abnormalities. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results